Cover Image
市場調查報告書

Actilyse的中國市場

Investigation Report on China Alteplase Market, 2010-2019

出版商 China Research and Intelligence 商品編碼 338985
出版日期 內容資訊 英文 20 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
Actilyse的中國市場 Investigation Report on China Alteplase Market, 2010-2019
出版日期: 2015年09月07日 內容資訊: 英文 20 Pages
簡介

Actilyse是第2代的血栓溶解劑,由於plasminogen的活性化和纖維蛋白的溶解而有溶化血塊的功能,尤其是急性心肌梗塞時可除去冠狀動脈的堵塞。中國的調查對象醫院的銷售額,從2005年的1200萬人民幣,到2014年的4000萬人民幣以上,以16.3%的年複合成長率(CAGR) 擴大。近幾年,由於中國青年人的心血管疾病患者數持續增加,Actilyse等抗血塊藥的市場機會非常大。

本報告提供中國的Actilyse的市場相關分析、Actilyse的特徵和認證情形、市場整體規模、各企業/各劑型的市場佔有率、價格趨勢、主要製造商簡介、今後的市場成長預測等的調查評估。

第1章 Actilyse的相關概念

  • 適應症
  • 全球市場的銷售情形

第2章 中國的Actilyse市場簡介

  • 中國國內的Actilyse的專利申請、核準情況
  • 主要製造商
  • 市場規模

第3章 中國國內的Actilyse銷售額分析 (過去5年份)

  • 銷售額
    • 整體銷售額
    • 各地區的銷售額
  • 銷售量
    • 整體銷售量
    • 各地區的銷售量

第4章 Actilyse的主要廠商的市場佔有率 (過去5年份)

  • 市場佔有率 (以金額為準)
  • 市場佔有率 (以數量為準)

第5章 中國國內的Actilyse的劑型 (過去5年份)

  • 各劑型的市場佔有率 (以金額為準)
  • 各劑型的市場佔有率 (以數量為準)

第6章 中國的醫院的Actilyse的參照價格

  • Boehringer-Ingelheim AG (德國)
  • Shandong Ahua Biopharmaceutical Co., Ltd

第7章 中國國內的Actilyse的主要製造商 (過去5年份)

  • Boehringer-Ingelheim AG (德國)
  • Shandong Ahua Biopharmaceutical Co., Ltd

第8章 中國國內的Actilyse市場未來展望 (今後5年份)

  • 市場規模的預測
  • 競爭環境的預測

圖表一覽

目錄
Product Code: 1509314

As the second generation of thrombolytic, anticoagulant factor alteplase can dissolve blood clots by activating plasminogen and then dissolving fibrin. For acute myocardial infarction, alteplase given intravenously can unclog coronary artery.

Plasmin working by resolving fibrous protein in clots takes up a small market share while plasminogen activator represented by alteplase developed by Genentech is the mainstream product in global market. In China, only Actilyse, a life-saving injection of Boehringer-Ingelheim AG with approved indications of acute myocardial infarction, (acute) pulmonary embolism and acute ischemic stroke is available. Having been approved by over 85 countries in the world, actilyse is marketed by Boehringer-Ingelheim AG in areas outside North America and Japan, by Genentech under the trade name of Activase since 1996 in the US and by Roche since 1999 in the Canada. Ever since its appearance, actilyse has been widely used to treat acute ischemic stroke.

According to CRI's market survey, the annual sales value of alteplase in sample hospitals rose from less than CNY 12 million in 2005 to over CNY 40 million in 2014 and CAGR during this period reached 16.3%. Boehringer-Ingelheim AG (Germany) and Shandong Ahua Biopharmaceutical Co., Ltd dominate the market with the former having the largest market share of over 90% for sales value in 2014.

Currently, the number of cardiovascular disease reports an increasing number of younger patients, high fatality and disability in China. According to the Report on Cardiovascular Diseases in China (2013), there are about 290 million people suffering from cardiovascular diseases. Since 2005, acute myocardial infarction has reported an increasing fatality and each year only 5% of 2.5 million patients per year can get treatment. Hence the vast market for anti-clotting drugs in China.

Readers can get at least the following information through this report:

  • market size of alteplase in China
  • competitive landscape of alteplase market in China
  • price of alteplase made by different enterprises in China
  • market outlook of alteplase in China

The author suggests the following groups of people purchase this report:

  • manufacturers of anti-clotting drugs
  • investors/research institutions interested in Chinese medicine market
  • -any interest in Chinese medicine market, please contact CRI for customized survey service

Table of Contents

1. Related Concepts of Alteplase

  • 1.1. Indication
  • 1.2. Sales Status in Global Market

2. Market Profile of Alteplase in China

  • 2.1. Patent and Approval Information of Alteplase in China
  • 2.2. Major Manufacturers
  • 2.3. Market Size

3. Survey on Alteplase sales in China, 2010-2014

  • 3.1. Sales Value
    • 3.1.1. Overall Sales Value
    • 3.1.2. Sales Value by Regions
  • 3.2. Sales Volume
    • 3.2.1. Overall Sales Volume
    • 3.2.2. Sales Volume by Regions

4. Survey on Market Share of Major Alteplase Manufacturers in China, 2010-2014

  • 4.1. Market Share by Sales Value
  • 4.2. Market Share by Sales Volume

5. Survey on Dosage Forms of Alteplase in China, 2010-2014

  • 5.1. Share of Different Dosage Forms by Sales Value
  • 5.2. Share of Different Dosage Forms by Sales Volume

6. Reference Price of Alteplase in Chinese Hospitals in 2014

  • 6.1. Boehringer-Ingelheim AG (Germany)
  • 6.2. Shandong Ahua Biopharmaceutical Co., Ltd

7. Major Manufacturers of Alteplase in Chinese Market, 2010-2014

  • 7.1. Boehringer-Ingelheim AG (Germany)
  • 7.2. Shandong Ahua Biopharmaceutical Co., Ltd

8. Market Outlook of Alteplase in China, 2015-2019

  • 8.1. Forecast of Market Size
  • 8.2. Forecast of Competitive Landscape

Table of Selected Charts

  • Chart Approval Information of Alteplase in China
  • Chart Alteplase Sales in China
  • Chart Sales Value of Alteplase in China, 2010-2014
  • Chart Sales Value of Alteplase in Some Regions in China, 2010-2014
  • Chart Sales Volume of Alteplase in China, 2010-2014
  • Chart Sales Volume of Alteplase in Some Regions in China, 2010-2014
  • Chart Sales Value and Market Share of Alteplase Made by Boehringer-Ingelheim (Germany) in China, 2010-2014
  • Chart Sales Value and Market Share of Alteplase Made by Shandong Ahua in China, 2010-2014
  • Chart Sales Value and Market Share of Alteplase Injection in China, 2010-2014
  • Chart Sales Volume and Market Share of Alteplase Tablet in China, 2010-2014
  • Chart Price of Alteplase Made by Boehringer-Ingelheim (Germany) in Some Chinese Cities in 2014
  • Chart Price of Alteplase Made by Shandong Ahua Biopharmaceutical Co., Ltd in Some Chinese Cities in 2014
Back to Top